China Medical System Investment Quality Review (00867.HK)

Quality score: 75/100 Valuation position: current price/base FV 1.48 Final signal: WATCHLIST

Core Conclusion

China Medical System is WATCHLIST. The quality score just clears the minimum watch threshold, but current price of HKD12.02 is far above conservative/base FV of HKD8.12.

Business And Quality

Five-year revenue CAGR is 4.3% and latest-year FCF is CNY0.25bn. The 75/100 score reflects acceptable business quality but limited FCF strength and evidence depth, especially around segment economics and governance follow-up.

Financial Audit

The review uses fiscal 2021-2025. Financial cash flows are primarily CNY while the stock trades in HKD. Five-year average FCF/Net Income is 0.74 and OCF/Net Income is 0.88. Latest net cash is CNY2.01bn. Market value is about HKD29.25bn on roughly 2.433bn shares.

Valuation

The valuation uses normalized FCF, the CNY 10Y government yield of 1.7% dated 2026-07-27, currency conversion into HKD, and separate balance-sheet adjustments. Price/base FV of 1.48 leaves no margin of safety.

Buy And Monitor

Current action is watchlist. Upgrade requires price/base FV below 0.70, quality score at least 75, and stronger mispricing evidence. Track revenue trend, FCF/Net Income, ROIC, net cash/debt, dividends, buybacks, and governance disclosure.

Risks

Risks include product and policy pressure, weak FCF repeatability, financial-asset haircuts, and capital allocation that does not protect ordinary shareholders. FCF/Net Income below 0.60 for two periods would require a lower FV.

Sources

Sources are public quote and financial data platforms, official filings or company IR, and ChinaBond for the CNY risk-free rate. Research only, not personalized investment advice.